Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWAP-9: ABCD-GENE Score-Guided vs Unguided DAPT De-Escalation in PCI Patients
NCT06588595Phase 4Recruiting
- Sponsor
- University of Florida
- Start
- Nov 2024
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prasugrel, ticagrelor, clopidogrel and aspirin in coronary artery disease (CAD) (2 arms), sponsored by University of Florida. Primary endpoint: P2Y12 Reaction Units at 30 days. Started Nov 2024; status: recruiting.
02
Drugs
prasugrelticagrelorclopidogrelaspirin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06588595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588595.